P-162 - INNOVATIVE PHASE-1 STUDY DESIGN IN HEALTHY PARTICIPANTS TO ENABLE RAPID PROGRESSION OF A FIRST-IN-CLASS ORAL PROTEASE INHIBITOR PF-07321332 TO PIVOTAL TRIALS IN COVID-19 PATIENTS.

R. Singh¹, S. Toussi², F. Hackman³, R. Obach⁴, A. Kalgutkar¹, G. Walker⁴, H. Shi⁴, X. Wan⁴, E. Kadar⁴, P. Chan⁵, L. Van Eyck⁶, S. Pawlak⁷, A. Anderson², M. Binks¹, G. Nucci¹, A. Bergman¹; ¹Pfizer Inc., Cambridge, MA, USA, ²Pfizer Inc., Pearl River, NY, USA, ³Pfizer Inc., Cambridge, United Kingdom, ⁴Pfizer Inc., Groton, CT, USA, ⁵Pfizer Inc., Sandwich, United Kingdom, ⁶Pfizer Inc., Brussels, Belgium, ⁷Pfizer Inc., New Haven, CT, USA.